Regression of Myocardial Dysfunction After Switching from Desferrioxamine to Deferiprone Therapy in β-Thalassemia Major Patients

REFERENCES

• Weatherall DJ, Clegg JB. The Thalassaemia Syndromes, 3rd edn. Blackwell Scientific Publications, London 1981
   Google Scholar
• Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic severe refractory anemia with hemochromatosis. Circulation 1964; 30: 698–705, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Crisaru D, Rachmilewitz EA, Mosseri M, Gotsman M, Lafair JS, Okon E, Goldfarb A, Hasin Y. Cardiopulmonary assessment in β-thalassemia major. Chest 1990; 98(5)1138–1142, [CSA]
   PubMedGoogle Scholar
• Freeman AP, Giles RW, Berdoukas V, Walsh WF, Chay D, Murray PC. Early left ventricular dysfunction and chelation therapy in thalassemia. Ann Intern Med 1983; 99(4)450–454, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kremastinos DT, Tontouzos PK, Vyssoulis GP, Vinitis CA, Vretan HF, Avgonstakis DG. Global and segmental left ventricular function in β-thalassemia. Cardiology 1985; 72(3)129–139, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lewis BS, Rachmilewitz EA, Amitai N, Halon DA, Gotsman MS. Left ventricular function in β‐thalassemia and the effect of multiple transfusions. Am Heart J 1978; 96(5)636–645, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Henry WL, Nienhuis AW, Wiener M, Miller DR, Canale VC, Piomelli S. Echocardiographic abnormalities in patients with transfusion-dependent anemia and secondary myocardial iron deposition. Am J Med 1978; 64(4)547–555, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Engle SJ, DiSessa TG, Perloff JK, Isabel-Jones J, Leighton J, Gross K, Friedman WF. Mitral valve E point to ventricular septal separation in infants and children. Am J Cardiol 1983; 52(8)1084–1087, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Massie BM, Schiller NB, Ratshin RA, Parmley WW. Mitral-septal separation: new echocardiographic index of left ventricular function. Am J Cardiol 1977; 39(7)1008–1016, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Lew W, Henning H, Schelbert H, Karliner JS. Assessment of mitral valve E point-septal separation as an index of left ventricular performance in patients with acute and previous myocardial infarction. Am J Cardiol 1978; 41(5)836–845, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Child JS, Krivokapich J, Perloff JK. Effect of left ventricular size on mitral E point to ventricular septal separation in assessment of cardiac performance. Am Heart J 1981; 101(6)797–805, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Vogel M, Anderson LJ, Holden S, Deanfield JE, Pennell DJ, Walker JM. Tissue Doppler echocardiography in patients with thalassaemia detects early myocardial dysfunction related to myocardial iron overload. Eur Heart J 2003; 24(1)113–119, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW. Efficacy of deferoxamine in preventing complication of iron overload in patients with thalassemia major. N Engl J Med 1994; 331(9)567–573, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R, Freedman MH, Nathan DG. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985; 312(25)1600–1603, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kamon J, Zeuner D, Brown J, Ades AE, Wonke B, Modell B. Lifetime treatment costs of β-thalassemia major. Clin Lab Haematol 1999; 21(6)377–385, [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Arden GB, Wonke B, Kennedy C, Huehns ER. Ocular changes in patients undergoing long-term desferrioxamine treatment. Br J Ophthalmol 1984; 68(12)873–877, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Olivieri NF, Buncic JR, Chew E, Gallant T, Harrison RV, Keenan N, Logan W, Mitchell D, Ricci G, Skarf B. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986; 314(14)869–873, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Brill PW, Winchester P, Giardina PJV. Cunningham-Rundles S. Deferoxamine-induced bone dysplasia in patients with thalassemia major. Am J Roentgenol 1991; 156(3)561–565, [CSA]
   PubMed Web of Science ®Google Scholar
• De Virgiliis S, Congia M, Frau F, Argiolu F, Diana G, Cucca F, Varsi A, Sanna G, Podda G, Fodde M. Deferoxamine-induced growth retardation in patients with thalassemia major. J Pediatr 1988; 113(4)661–669, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, Sheppard L. Effective chelation of iron in β thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Br Med J 1987; 295(6612)1509–1512, [CSA]
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Aldouri MA, Sheppard l, Hoffbrand AV. 1,2-Dimethyl-3-hydroxypyrid-4-one. An orally active chelator for treatment of iron overload. Lancet 1987; 1(8545)1294–1295, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Vreugdenhil G, Swaak AJ, Kontoghiorghes GJ, van Eijk HG. Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients. Lancet 1989; 2(8676)1398–1399, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, Goddard JG, Sheppard L, Barr J, Nortey P. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies. Br J Haematol 1990; 76(2)295–300, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Tondury P, Kontoghiorghes GJ, Ridolfi-Luthy A, Hirt A, Hoffbrand AV, Lottenbach AM, Sonderegger T, Wagner HP. L1 (1.2-dimethvl-3-hvdroxvpvrid-4-one) for iron chelation in patients with β-thalassaemia major. Br J Haematol 1990; 76(4)550–553, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Agarwal MB, Gupte SS, Viswanathan C, Vasandani D, Ramanathan J, Desai N, Puniyani RR, Chhablani AT. Long-term assessment of efficacy and safety of L1 an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol 1992; 82(2)460–466, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• AL-Refaie FN, Wonke B, Hoffbrand AV, Wicken DG, Nortey P, Kontoghiorghes GJ. Efficacy and possible adverse effects of the oral chelator L1 in thalassemia major. Blood 1992; 80(3)593–599, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Koren G, Matsui D, Liu PP, Blendis L, Cameron R, McClelland RA, Templeton DM. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 1992; 15(10)2741–2748, [CSA]
   Google Scholar
• Collins AF, Fassos FF, Stobie S, Lewis N, Shaw D, Fry M, Templeton DM, McClelland RA, Koren G, Olivieri NF. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood 1994; 83(8)2329–2333, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Al-Refaie FN, Hershko C, Hoffbrand AV, Kosaryan M, Olivieri NF, Tondury P, Wonke B. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on oral iron chelators. Br J Haematol 1995; 91(1)224–229, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar